2024-510614-33-00Active, not recruitingPhase 2
5-Aminolevulinic Acid (5-ALA) for Intraoperative Imaging in Patients with Ovarian Cancer – a Single Center Feasibility Study (ILLUMINATE)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 May 2026
Brief summary (registry, in English)
To evaluate the efficacy of intraoperative imaging using 5-ALA to detect ovarian cancer tumour manifestations that would not have been identified as such by normal light and palpation and would not have been scheduled for resection.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Jul 2024
- Start date
- 10 Jun 2025
- Lead sponsor
- Rheinische Friedrich-Wilhelms-Universitaet Bonn
- Diseases
- Ovarian cancer
- EU CT number
- 2024-510614-33-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Simultaneous participation in another surgical clinical trial, or participation in a clinical trial taking an investigational product, up to 30 days after last IMP intake in that clinical trial
- Known or persistent abuse of medication, drugs or alcohol
- Fertility-preserving surgical therapy
- Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure
Other illness
- Known history of hypersensitivity to porphyrins
- Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
- Presence of another type of cancer in the final histology
Lab values
- Restricted kidney function (GFR < 50 ml/min)
- Restricted liver function (bilirubin / AST/ALT > 3x ULN)
- Current (positive pregnancy test, e.g. beta-hCG test in serum) or planned pregnancy or nursing women
Other
- Subject without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial
- Known secondary diagnoses that present a risk when using the IMP, in particular acute and chronic porphyria
- Preoperative classification of the patient as inoperable
Who the study is looking for
- Written informed consent to participate in this clinical trial in accordance with local regulations and the ethical review board governing this clinical trial
- Female
- Age ≥ 18 years
- Confirmed or suspected ovarian cancer or ovarian cancer recurrence
- Planned surgical treatment by staging or debulking laparotomy at the Department of Gynecology and Gynecologic Oncology at the University Hospital Bonn. Interval debulking operations after previous neoadjuvant chemotherapy are also included.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Bonn AöR | Bonn | Germany | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.